Ribavirin: 3 agencies, 2005–2016
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused ribavirin: all 6 decisive outcomes across 3 agencies were positive or positive with restrictions.
Assessment has run over 10.7 years, from 2 Nov 2005 at TLV (Sweden) to 2016 at PBAC (Australia).
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), SMC (Scotland) and AWMSG (Wales) among them — hold no record for ribavirin at all.
Nothing has been added since 2016; on this evidence the file is dormant.
3 distinct indication wordings are recorded for ribavirin by the agency that label one in English (PBAC).
4 of these 7 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess ribavirin, on 2 Nov 2005; PBAC (Australia) did not open a file until 2015 — an unusually long tail of 9.7 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 3 of 7 dated records fall in 2015 alone.
2 of the 3 agencies here assessed ribavirin more than once, PBAC (Australia) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 3 of the 18 agencies here have assessed ribavirin.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2016 | Chronic hepatitis C virus infection | The PBAC recommended the listing of ribavirin 200 mg, for use in combination therapy with … | source |
| PBAC (Australia) | 2016 | Chronic hepatitis C virus infection | The PBAC recommended the listing of ribavirin in combination with daclatasvir and sofosbuv… | source |
| PHARMAC (New Zealand) | 7 May 2015 | RSV infection, recipients of lung or allogeneic stem cell transplants | PTAC advice: Recommended for funding with no priority | source |
| TLV (Sweden) | 28 Feb 2012 | Rebetol ingår åter i högkostnadsskyddet | general subsidy | source |
| TLV (Sweden) | 2 Nov 2005 | Subvention för Rebetol | general subsidy | source |
2 further decisions for ribavirin, across 1 agency, are not shown here.
Related molecules
- sofosbuvir / velpatasvir / voxilaprevir — divergent outcome (recommended vs no benefit) on a shared indication
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
Coverage: 7 decisions for ribavirin from 3 agencies, 2005 to 2016. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.